Meditrina Pharmaceuticals, Inc. identifies and repurposes already marketed therapies and product candidates at advanced stages of development for new indications focused on improving women’s health disorders with unmet medical needs. The Company’s initial focus is in overlooked therapeutic areas that affect millions of women each year. These areas include gynecologic and aromatase-meditated conditions such as endometriosis and uterine fibroids.
Meditrina’s proprietary therapies have the potential to significantly alter the way certain women’s reproductive system disorders are treated. MPI-676 is a product candidate containing anastrozole, an aromatase inhibitor (AI) with a well-established, multi-year chronic safety and tolerability profile that Meditrina is repurposing to improve patient outcomes for this indication, together with estrogen and progestin. Currently used for the chronic treatment of estrogen-dependent breast cancer in postmenopausal women, AIs are being investigated in a variety of women’s health conditions. Meditrina holds the exclusive worldwide rights to patent applications covering uses of AIs in gynecologic indications.
The Company was founded in 2006 by a team of entrepreneurs and drug developers based on the work of world-renowned researchers and clinicians at Wayne State University and Mount Sinai Hospital at the University of Toronto. Meditrina’s founders had a keen interest in targeting unmet needs in the women’s healthcare arena, which has been underserved by large pharmaceutical companies. The management team has substantial experience in clinical development, commercialization and company building. In addition, Meditrina has recruited the premiere researchers and doctors in the women’s health industry to its scientific team and medical advisory board. These acclaimed advisors work closely with the Company to advance its clinical program.
By focusing on late-stage development and commercialization of its product candidates, Meditrina is executing against a capital-efficient business model that that maximizes the potential for new products, the benefits for patients, and the returns for investors.